Department of Aesthetic and Reconstructive Breast Surgery, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Am Surg. 2023 Dec;89(12):6157-6171. doi: 10.1177/00031348231191200. Epub 2023 Jul 24.
Prognostic nutritional index (PNI) is a comprehensive reflection of the nutritional and immune status of the patient, which is closely related to the ability of the organism to clear tumor cells and reduce local recurrence. Several findings suggested that PNI was a prognostic indicator for breast cancer, but the conclusions were conflicting. We aimed to comprehensively elucidate the prognostic value of PNI in breast cancer patients.
Relevant studies in PubMed, Embase, Cochrane Library, and Web of Science databases were searched through March 2023. Data extraction and literature quality assessment of the screened studies were performed. The associations between PNI and overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in breast cancer patients who received clinical treatment were assessed by hazard ratios () and 95% confidence intervals ().
A total of 7 studies involving 2212 patients met the inclusion criteria. High PNI was a favorable independent predictor of prolonged OS and PFS after clinical treatment in breast cancer patients compared to low PNI (for OS: = .38, 95% .31 ∼ .46, < .001; for DFS: = .32, 95% .19 ∼ .51, < .001). In subgroup analysis, high PNI was a prognostic factor for extended DFS in the context of a study sample size ≥300 ( = .39, 95% .28 ∼ .54, < .001) and patients not receiving neoadjuvant chemotherapy ( = .51, 95% .37 ∼ .70, < .001).
The PNI has a significant correlation with the prognosis of breast cancer patients. We suggest that individualized targeted treatment and long-term surveillance should be implemented for patients with different levels of PNI.
预后营养指数(PNI)是对患者营养和免疫状态的综合反映,与机体清除肿瘤细胞和减少局部复发的能力密切相关。一些研究结果表明,PNI 是乳腺癌的预后指标,但结论存在争议。我们旨在综合阐明 PNI 对乳腺癌患者的预后价值。
通过检索 PubMed、Embase、Cochrane Library 和 Web of Science 数据库,检索截止日期为 2023 年 3 月。对筛选出的研究进行数据提取和文献质量评估。采用风险比(HR)和 95%置信区间(CI)评估 PNI 与接受临床治疗的乳腺癌患者的总生存(OS)、无病生存(DFS)和无进展生存(PFS)之间的相关性。
共纳入 7 项研究,共计 2212 例患者符合纳入标准。与低 PNI 相比,高 PNI 是乳腺癌患者接受临床治疗后 OS 和 PFS 延长的有利独立预测因素(OS:HR =.38,95%CI .31 ~.46,<.001;DFS:HR =.32,95%CI .19 ~.51,<.001)。亚组分析显示,在研究样本量≥300(HR =.39,95%CI .28 ~.54,<.001)和未接受新辅助化疗的患者(HR =.51,95%CI .37 ~.70,<.001)中,高 PNI 是延长 DFS 的预后因素。
PNI 与乳腺癌患者的预后显著相关。我们建议,应根据 PNI 水平的不同,对患者实施个体化的靶向治疗和长期监测。